D
David G Jones
Researcher at GlaxoSmithKline
Publications - 6
Citations - 225
David G Jones is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Ketone & Enone. The author has an hindex of 3, co-authored 6 publications receiving 215 citations. Previous affiliations of David G Jones include DuPont.
Papers
More filters
Journal ArticleDOI
Identification and Structure−Activity Relationship of Phenolic Acyl Hydrazones as Selective Agonists for the Estrogen-Related Orphan Nuclear Receptors ERRβ and ERRγ
William J. Zuercher,Stephanie Gaillard,Lisa A. Orband-Miller,Esther Y. Chao,Barry G. Shearer,David G Jones,Aaron B. Miller,Jon L. Collins,Donald P. McDonnell,Timothy M. Willson +9 more
TL;DR: The first small molecule agonists of the estrogen-related receptors have been identified and show binding to ERRgamma with remarkable selectivity over the classical estrogen receptors.
Journal ArticleDOI
2'-substituted chalcone derivatives as inhibitors of interleukin-1 biosynthesis
Douglas Guy Batt,Robin Goodman,David G Jones,Janet S. Kerr,L. R. Mantegna,Candice McAllister,Robert Newton,Sherrill Nurnberg,P. K. Welch,Maryanne B. Covington +9 more
TL;DR: A series of 2'-substituted chalcone derivatives has been found to show potent inhibition of the production of IL-1 beta from human peripheral blood monocytes stimulated with lipopolysaccharide, suggesting a degree of selectivity which would not be expected for simple, nonspecific alkylating agents.
Patent
Indazoles used to treat estrogen receptor beta mediated disorders
Christopher N. Johnson,David G Jones,Liang Xi,Macpherson David T,Aaron B. Miller,Naylor Antoinette,Steven J. Stanway,Andrew K. Takle,Giancarlo Trani +8 more
TL;DR: The present invention relates to novel indazole derivatives (I) having pharmacological activity, processes for their preparation, compositions containing them and uses of these compounds in the treatment of estrogen receptor beta mediated diseases as discussed by the authors.
Patent
Substituted 4-hydroxy-n- (4-hydroxyphenyl) indoles as estrogenic agents
Christopher Norbert Johnson,David G Jones,Liang Xi,Macpherson David T,Aaron B. Miller,Steven James Stanway,Andrew K. Takle,Giancarlo Trani,Antoinette Wilson +8 more
TL;DR: The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.
Journal ArticleDOI
2′‐Substituted Chalcone Derivatives as Inhibitors of Interleukin‐1 Biosynthesis.
Douglas Guy Batt,Robin Goodman,David G Jones,Janet S. Kerr,L. R. Mantegna,Candice McAllister,Robert Newton,Sherrill Nurnberg,P. K. Welch,Maryanne B. Covington +9 more
TL;DR: A series of 2-substituted chalcone derivatives has been found to show potent inhibition of the production of IL-1 beta from human peripheral blood monocytes stimulated with lipopolysaccharide (LPS), with IC50 values in the 0.2-5.0-microM range as mentioned in this paper.